Mave

Mave sits at the intersection of consumer neurotechnology, wearable health devices, and digital mental wellness. Its named product, the Mave Wearable Headset, uses non-invasive transcranial direct current stimulation (tDCS) and is designed around short daily sessions, with stated goals including focus, mood, sleep, and stress regulation. A companion app supports session management and progress tracking, giving the product a software component alongside the hardware. The company’s categories also include mental health, health care, psychology, and therapeutics, but its public company description emphasizes virtual therapy and psychiatric support while its product information centers on a neurostimulation headset. That difference makes it difficult to establish whether the primary competitive frame is clinical digital care or consumer neurotechnology. Mave has disclosed seed-stage funding, including a $2.1 million round led by Blume Ventures, and a reported employee range of 11–50. Those indicators describe an early-stage company, not evidence of market share or clinical efficacy.

Mave’s disclosed financing history shows progression from a $719,653 pre-seed round on April 3, 2024, to a $2.1 million seed round on March 18, 2026. The later round, led by Blume Ventures, accounts for most of the company’s $2,819,653 in reported total funding and coincides with the launch of its wearable headset. The product launch is dated February 18, 2026; its description states that pre-orders were available in the United States and India and that shipping was due to start in April 2026. Because that date has passed, the launch marks a product and commercialization inflection point rather than a future milestone, though no shipment volumes or sales results are disclosed. A June 28, 2026 growth signal characterized both customer and funding trends as improving, but it did not provide underlying figures. The reported employee band is 11–50, with no hiring announcements or headcount time series to establish the pace of team growth. The next measurable indicators of trajectory would be product adoption, customer retention, and evidence clarifying how the headset relates to the company’s broader digital mental-health services.